The FEELLIFE nebulization research institute opens the new
Shenzhen, Guangdong, Aug 21, 2021 (GLOBE NEWSWIRE) – Currently, the COVID-19 epidemic around the world is not only a challenge for human beings, but also new thinking and new exploration of the epidemic for us. How to more effectively mitigate the spread of the epidemic is a pressing issue for all of us. Recently, clinical research data of inhalable aerosol Adenovirus recombinant vector vaccine for COVID-19 jointly developed by vaccine company CanSino Bio and professional team under the leadership of Academician Chen Wei, Chinese Academy of Engineering （CAE）, were published in the lancet, which is also the result of the first clinical trial of the COVID-19 vaccine published worldwide.
According to clinical research data of the inhalable aerosol vaccine Recombinant vector adenovirus for COVID-19 (Ad5-nCoV) jointly developed by the vaccine company CanSino Bio and the professional team under the leadership of Academician Chen Wei, of the Academy Chinese Engineering (CAE), the results of the interim analysis of the phase III clinical trial conducted in Pakistan showed that the protective efficacy of a single injection against critically ill covid patients after a single injection was 100% and the overall protective efficacy was 74.8%. There were no serious side effects related to the vaccine. The phase II clinical trial was launched on April 12, 2021. Data from the two phase clinical trials were published in the internationally renowned medical journal the lancet. He says the vaccine is safe, well tolerated and has no serious adverse effects, which shows future changes in COVID-19 vaccination methods, and it is also the advancement of mankind in the history of epidemic prevention. According to the relevant research results, based on the completion of the previous COVID-19 vaccine injection, in addition, when people receive the inhalable vaccine, they can effectively resist the mutant strain of COVID. While the epidemic is still severe, it shines a ray of light on all human beings.
FEELLIFE Nebulization Research Institute opens new chapter in inhalation vaccine mission
The Ad5-nCoV of the national scientific research and R&D team adopts nebulization vaccination. The vaccine is nebulized into tiny particles with a nebulizer, which penetrates the respiratory mucosa through respiration and inhalation, and quickly establishes immune protection. In addition to the scientific results of the vaccine, there is also a nebulizer which plays a major determining role.
The FEELLIFE nebulizer is one of the nebulizers for vaccine nebulization, and it uses advanced technology to help the development of vaccination. FEELLIFE is an international medical company integrating the R&D and production of portable micro-grid nebulizers. It was selected as a national high-tech enterprise in 2016 with hundreds of core technologies and patents. It aims to provide humans with the third route of administration of the dosage.
FEELLIFE Nebulization Research Institute actively responds to China’s speedy national epidemic prevention measures and actions, and leads the scientific research team to develop suitable nebulized vaccines to create the future of intelligent technology, create the era of the core of nebulization technology. In step with our times, we have developed AirRight Medical grade nebulizers, combined with epidemic prevention requirements, must be strict, rigorous and careful to ensure that every nebulized vaccine can be vaccinated effectively and safely with FEELLIFE nebulizers. In the future, nebulized vaccines will be successfully vaccinated in the Chinese, if not in all human beings. achieve fast, effective and safe vaccination, reduce vaccine consumables consumables, improve vaccination efficiency and quickly establish triple protection: mucosal immunity, cellular immunity and humoral immunity. The epidemic is still serious for the moment, the difficult mission must be long.
By fighting COVID-19, humans will win. We FEELLIFE devote everything to preparing, fighting, a bright future and freedom with you all.
In the future, the FEELLIFE nebulizer may become one of the designated nebulizers for nebulized inhalation vaccines. The special nebulizer nebulized vaccines, FEELLIFE nebulizer Aerial right not only compensates for the inability of many nebulizers to achieve controllable volume in medical applications, adjustable functions, modifying the traditional dosing mode, solving many injection problems, but also pioneering to provide a powerful and effective solution for the aerosol vaccine research and development. FEELLIFE Nebulization Research Institute is actively involved in nebulization, providing safe, effective and reliable nebulization medical services for humans, and globally aiding nebulization vaccine development.
The epidemic is ruthless and there is love in the world. What FEELLIFE must do is do a good job on the front line of the company and the country, unite in the prevention and control of national epidemics and help in the development of inhaled aerosol vaccines through the development of nebulizers. .
In the future, with the advent of inhalable vaccines, COVID-19 will soon disappear, which will be a milestone for humans.
Company ： Feellife Health Inc
Contact Person: WoLong
Email: [email protected]
Location: 202, 2nd Floor, Deweisen Building, No.016, Gaoxin South 7th Road, High-tech Zone, Shenzhen, Guangdong, China
DISCLAIMER. IN NO EVENT SHALL OUR PR COMPANY BE LIABLE TO YOU OR ANY OTHER PERSON FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR OF OPPORTUNITIES, EVEN IF NOTICE OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE AND WHATEVER THE CAUSE OF ACTION ON WHICH SUCH CLAIM IS BASED, INCLUDING, WITHOUT LIMITATION, ANY CLAIM ARISING OUT OF OR IN CONNECTION WITH ANY CONTENT, INCLUDING, WITHOUT LIMITATION, AUDIO, PHOTOGRAPHS, AND VIDEOS, OR THE ACCURACY, RELIABILITY OR LEGALITY OF ANY STATEMENT MADE OR OMITTED IN ANY advertisement, sponsorship, endorsement, testimony, opinion or other related statement or criticism to the product or service appearing on the websites or in ANY publication or article disseminated through the websites.